查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
激素避孕药市场 - 全球行业规模、份额、趋势、机会和预测，2018-2028 年：按方法、按激素、按地区细分、竞争
市场调查报告书
商品编码
1255243

激素避孕药市场 - 全球行业规模、份额、趋势、机会和预测，2018-2028 年：按方法、按激素、按地区细分、竞争

Hormonal Contraceptives Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Method, By Hormone, By Region, and Competition
出版日期: | 出版商: TechSci Research | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

在预测期内，全球激素避孕药市场预计将出现惊人的增长。

这是由于对口服避孕药的使用及其预防意外怀孕的有效性以及人口控制的认识提高，这大大增加了世界各地对激素避孕药的需求。我认为是有的。 此外，激素避孕药的采用显着增加以及不同年龄段女性对安全生活意识的增强将进一步增加对各种激素避孕方法的需求，到 2028 年，预计将推动市场增长。 例如，2021 年 4 月，由 Mayne Pharma 上市的屈螺酮和雌四醇组合片剂 Nextstellis 被美国食品和药物管理局批准用于预防妊娠，成为首批含有天然雌激素的组合片剂之一。 此外，人们对计划生育的兴趣日益浓厚、有利的政府法规以及荷尔蒙避孕药的进步预计将进□□一步增加对荷尔蒙避孕药的需求并支持市场的增长。 同样，各国政府为增加避孕产品所做的支持性努力也将推动预测期内的市场增长。 例如，2019 年 7 月，Allergen Plc 与音乐家兼演员 Ashley Tisdale 合作开展了名为“Women Who Know”的宣传活动。 世界卫生组织提供了关于使用宫内节育器、黄体酮注射液和植入物等荷尔蒙避孕药的指南，以帮助高危女性感染艾滋病毒。

意外怀孕增加

影响全球激素避孕药市场增长的主要因素是城市化进程加快导致计划生育意识增强，以及对个人生活方式改变的影响。 许多政府机构正在采取措施控制人口规模。 然而，激素避孕药被认为比避孕套和隔膜等非激素避孕药更可靠，而且有大量女性人口有计划外的需求。 这可能会在预测期内推动荷尔蒙避孕药市场的增长。 根据 PubMed 的一篇文章，美国每年约有 300 万例意外怀孕。 因此，对计划外避孕需求的增加显着增加了需求，进一步推动了预测期内市场的增长。 根据 NCBI 的研究，每 1,000 名正确服用避孕药的女性中只有 1 人会怀孕。

新型避孕药的研製

领先的公司正在创新生产副作用较少的可咀嚼的低剂量口服避孕药。 咀嚼式避孕药试图减少副作用，同时让患者更容易每天使用避孕药。 开发和销售可咀嚼的低剂量口服避孕药的领先公司包括 Lupin Pharmaceuticals、Walter Chilcott 和 Watson Pharmaceuticals。 根据联合国 2019 年避孕方法调查，在至少五分之一的国家/地区，单一方法占所有避孕方法的 50% 以上。

近期发展

  • 例如，2021 年 4 月，Mayne Pharma 获得了美国 FDA 批准用于预防怀孕的 NEXTSTELLIS 和 Estetrol。 它是唯一含有 E4 和植物来源雌激素的避孕药，与其他雌激素相比几乎没有显着优势。
  • 例如，2021 年 7 月，MHRA 开始在英国药店柜檯销售避孕药。 两个避孕药品牌，Hana 和 Lovima，只需咨询您的药剂师即可在非处方药店出售去氧孕烯合成黄体酮。
  • 例如，2021 年 6 月，Teva Pharmaceuticals USA 推出了仿製药 NuvaRing、乙炔雌二醇和依托孕烯阴道环避孕药。
  • 2020 年 2 月 Agile Therapeutics 的 Twirla 获得美国 FDA 批准，Twirla 是一种含有左炔诺孕酮和炔雌醇的透皮贴剂。

可自定义

根据市场数据，TechSci Research 根据公司的具体需求提供定制服务。 该报告可以定制为：

公司信息

  • 对其他市场参与者（最多 5 家公司）进行深入分析和概况分析

内容

第 1 章概述

  • 市场定义
  • 市场范围
    • 目标市场
    • 研究目标年份
    • 主要市场细分

第二章研究方法论

  • 调查目的
  • 基线调查方法
  • 主要行业合作伙伴
  • 主要协会和次要信息
  • 调查方法
  • 数据三角测量和验证
  • 假设和限制

第 3 章执行摘要

  • 市场概览
  • 主要市场细分概述
  • 主要市场参与者概览
  • 主要地区/国家概览
  • 市场驱动因素、挑战和趋势

第 4 章 VOC（客户之声）

第5章临床试验分析

  • 正在进行的临床试验
  • 已完成临床试验
  • 已完成临床试验
  • 管道细分（按开发阶段）
  • 管道细分（按状态）
  • 管道细分（按研究类型）
  • 按地区划分的渠道细分
  • 临床试验热图

第 6 章激素避孕药的全球市场展望

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 按方法（药丸、宫内节育器、注射剂、阴道环、植入物等）
    • 按激素分类（联合激素避孕药与单独使用孕激素的比较）
    • 按地区
    • 按公司分类（2022 年）
  • 市场地图
    • 通过方法
    • 荷尔蒙
    • 按地区

第 7 章北美激素避孕药市场展望

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 通过方法
    • 荷尔蒙
    • 按国家
  • 北美：国家/地区分析
    • 美国
    • 加拿大
    • 墨西哥

第 8 章欧洲激素避孕药市场展望

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 通过方法
    • 荷尔蒙
    • 按国家
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第 9 章亚太地区激素避孕药市场展望

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 通过方法
    • 荷尔蒙
    • 按国家
  • 亚太地区：国家/地区分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第 10 章南美洲激素避孕药市场展望

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 通过方法
    • 荷尔蒙
    • 按国家
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 11 章中东和非洲激素避孕药市场展望

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 通过方法
    • 荷尔蒙
    • 按国家
  • MEA：国家分析
    • 南非荷尔蒙避孕药
    • 沙特阿拉伯的荷尔蒙避孕药
    • 阿联酋荷尔蒙避孕药
    • 土耳其荷尔蒙避孕药
    • 埃及荷尔蒙避孕药

第 12 章市场动态

  • 司机
  • 任务

第13章市场趋势与发展

  • 近期趋势
  • M&A（併购）
  • 产品发布

第14章竞争格局

  • Abbvie, Inc.
  • Afaxys, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Bayer AG
  • Merck & Co. Inc.
  • Organon Group of Companies
  • Pfizer Inc.
  • Johnson & Johnson
  • Lupin Pharmaceuticals Inc.
  • Pregna International Ltd.

第 15 章战略建议

简介目录
Product Code: 14350

The Global Hormonal Contraceptives Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing awareness regarding the usage of oral contraceptives and their benefits for preventing unintended pregnancy, and population control significantly increased the demand for hormonal contraceptives across different parts of the globe. Additionally, the adoption of hormonal contraceptives has significantly increased, and increasing awareness among women of different age groups for leading a safe life is further expected to increase the demand for different hormonal contraceptive procedures, thereby fuelling the market growth through 2028. For instance, in April 2021, the Food and Drug Administration approved a combination of drospirenone and estetrol tablet Nextstellis marketed by Mayne Pharma for preventing pregnancy, one of the first combination pills containing naturally occurring estrogen. Furthermore, increasing focus on family planning, favorable regulations by the government, and advancements in hormonal contraception are further expected to increase the demand for hormonal contraceptives, thereby supporting the market growth. Similarly, supportive initiatives by various governments to increase contraceptive products will propel the growth of the market during the forecast period. For instance, in July 2019, Allergen Plc collaborated with Ashley Tisdale, a musician, and actress, for the awareness campaign "Women Who Know." The World Health Organization provided guidelines, for the usage of hormonal contraceptives, such as intrauterine devices, progestogen injectables, and implants, for women at greater risk of HIV.

Increasing Number of Unplanned Pregnancies

The main factors that affect the growth of the global hormonal contraceptives market are the increasing awareness of family planning due to growing urbanization growing g influence on the changing lifestyle of individuals. Many government organizations are taking initiatives to control the population size. However, hormonal contraceptives are considered more reliable than non-hormonal contraceptives such as condoms and diaphragms, and there is a huge chunk of the female population with unplanned needs. This in turn may help the hormonal contraceptives market grow during the forecast period. As per a publication in PubMed, the number of unintended pregnancies in the U.S. is around three million annually. So, the growing unplanned need for contraceptives significantly increased the demand, which is further boosting the growth of the market in the forecast period. According to NCBI research, only 1 woman out of 1000 women gets pregnant if they take these contraceptives properly.

Development of New Contraceptives

Major companies are innovating to manufacture chewable low-dose oral contraceptives that reduce side effects. The chewable contraceptive initiative was an attempt to reduce side effects while at the same time making it easier for the patients to get into a daily regimen of using this contraceptive. Some of the top companies that develop and sell chewable low-dose oral contraceptives are Lupin pharmaceuticals, Walter Chilcott, and Watson pharmaceuticals. According to the United Nations Contraceptive Use by Method 2019 study, a single method accounts for 50% or more of all contraceptive use in at least one out of every five nations or regions.

Market Segmentation

The global hormonal contraceptive market can be segmented by method, hormone, and region. Based on the method, the market can be segmented into Pills, Intrauterine Devices, Injectables, Vaginal rings, implants, and Others. Based on hormones, the market can be divided into Combination Hormonal Contraceptives v/s Progestin Only. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global hormonal contraceptives market on account of increasing unplanned pregnancies with low-cost product in the country.

Market Players

Abbvie, Inc., Afaxys, Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Merck & Co. Inc., Organon Group of Companies, Pfizer Inc., Johnson & Johnson, Lupin Pharmaceuticals Inc., Pregna International Ltd. are some of the leading players operating in the Global Hormonal Contraceptives Market.

Recent Developments

  • For instance, in April 2021, Mayne Pharma received U.S. FDA approval for NEXTSTELLIS and estetrol for avoiding pregnancy. It is the only contraceptive pill with E4 and a plant-based estrogen having few important benefits compared to other estrogens.
  • For instance, in July 2021, the MHRA launched the OTC sale of contraceptive pills in U.K. pharmacies. Two contraceptive pill brands, Hana and Lovima, are selling desogestrel- synthetic progesterone, OTC, with a brief consultation with a pharmacist.
  • For instance, in June 2021, Teva Pharmaceuticals USA launched the generic form of NuvaRing, Ethinyl estradiol, and etonogestrel vaginal ring contraceptive.
  • In February 2020, Agile Therapeutics, Inc. received U.S. FDA approval for the Twirla, a transdermal patch containing levonorgestrel and Ethinylestradiol.

Report Scope

In this report, global hormonal contraceptives market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hormonal Contraceptives Market, By Method:

  • Pill
  • Intrauterine Device
  • Injectable
  • Vaginal Ring
  • Implant
  • Others

Hormonal Contraceptives Market, By Hormone:

  • Combination Hormonal Contraceptives
  • Progestin Only

Hormonal Contraceptives Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Hormonal Contraceptives Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Hormonal Contraceptives Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Method (Pill, Intrauterine Device, Injectable, Vaginal Ring, Implant, Others)
    • 6.2.2. By Hormone (Combination Hormonal Contraceptives v/s Progestin Only)
    • 6.2.3. By Region
    • 6.2.4. By Company (2022)
  • 6.3. Market Map
    • 6.3.1. By Method
    • 6.3.2. By Hormone
    • 6.3.3. By Region

7. North America Hormonal Contraceptives Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Method
    • 7.2.2. By Hormone
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Hormonal Contraceptives Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Method
        • 7.3.1.2.2. By Hormone
    • 7.3.2. Canada Hormonal Contraceptives Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Method
        • 7.3.2.2.2. By Hormone
    • 7.3.3. Mexico Hormonal Contraceptives Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Method
        • 7.3.3.2.2. By Hormone

8. Europe Hormonal Contraceptives Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Method
    • 8.2.2. By Hormone
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Hormonal Contraceptives Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Method
        • 8.3.1.2.2. By Hormone
    • 8.3.2. Germany Hormonal Contraceptives Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Method
        • 8.3.2.2.2. By Hormone
    • 8.3.3. United Kingdom Hormonal Contraceptives Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Method
        • 8.3.3.2.2. By Hormone
    • 8.3.4. Italy Hormonal Contraceptives Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Method
        • 8.3.4.2.2. By Hormone
    • 8.3.5. Spain Hormonal Contraceptives Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Method
        • 8.3.5.2.2. By Hormone

9. Asia-Pacific Hormonal Contraceptives Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Method
    • 9.2.2. By Hormone
    • 9.2.3. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Hormonal Contraceptives Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Method
        • 9.3.1.2.2. By Hormone
    • 9.3.2. India Hormonal Contraceptives Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Method
        • 9.3.2.2.2. By Hormone
    • 9.3.3. Japan Hormonal Contraceptives Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Method
        • 9.3.3.2.2. By Hormone
    • 9.3.4. South Korea Hormonal Contraceptives Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Method
        • 9.3.4.2.2. By Hormone
    • 9.3.5. Australia Hormonal Contraceptives Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Method
        • 9.3.5.2.2. By Hormone

10. South America Hormonal Contraceptives Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Method
    • 10.2.2. By Hormone
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Hormonal Contraceptives Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Method
        • 10.3.1.2.2. By Hormone
    • 10.3.2. Argentina Hormonal Contraceptives Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Method
        • 10.3.2.2.2. By Hormone
    • 10.3.3. Colombia Hormonal Contraceptives Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Method
        • 10.3.3.2.2. By Hormone

11. Middle East and Africa Hormonal Contraceptives Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Method
    • 11.2.2. By Hormone
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Hormonal Contraceptives Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Method
        • 11.3.1.2.2. By Hormone
    • 11.3.2. Saudi Arabia Hormonal Contraceptives Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Method
        • 11.3.2.2.2. By Hormone
    • 11.3.3. UAE Hormonal Contraceptives Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Method
        • 11.3.3.2.2. By Hormone
    • 11.3.4. Turkey Hormonal Contraceptives Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Method
        • 11.3.4.2.2. By Hormone
    • 11.3.5. Egypt Hormonal Contraceptives Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Method
        • 11.3.5.2.2. By Hormone

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. Abbvie, Inc.
    • 14.6.2. Afaxys, Inc.
    • 14.6.3. Teva Pharmaceuticals Industries Ltd.
    • 14.6.4. Bayer AG
    • 14.6.5. Merck & Co. Inc.
    • 14.6.6. Organon Group of Companies
    • 14.6.7. Pfizer Inc.
    • 14.6.8. Johnson & Johnson
    • 14.6.9. Lupin Pharmaceuticals Inc.
    • 14.6.10. Pregna International Ltd.

15. Strategic Recommendations